MFN2 and diabetes mellitus: Collectively, our study demonstrated that cordycepin could be a potential cardioprotective agent for myocardial I/R injury in diabetes, and established a novel mechanism by which upregulated AMPK/Mfn2-dependent mitochondrial fusion contributes to the cardioprotective role of cordycepin.